Page URL: https://www.bionews.org.uk/page_93856

Gene therapy approved in Europe for first time

5 November 2012
Appeared in BioNews 680

The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat the rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved in Europe or North America and offers the first therapeutic treatment for people with LPLD.

'The final approval of Glybera from the [European Commission] marks a major step forward in making gene therapies available not only for LPLD but also for a large number of rare diseases with a very high unmet medical need', said Mr Jörn Aldag, CEO of uniQure, which developed Glybera.

At a cost of €1.2million per patient, Glybera is the most expensive medicine currently available. However, Mr Aldag said this is a fair price to pay for a therapy that restores natural body function and is not just a short-term fix.

In an interview with Reuters he said, '[Glybera] provides higher benefit to patients than the classical protein replacement strategy and this is why we think we should be fairly and adequately compensated'.

After the first successful treatment of severe combined immunodeficiency (SCID) using gene therapy in 1990, development of the technique stumbled. One gene therapy patient in Arizona died and two study participants in France developed leukaemia during the SCID gene therapy trial.  Although approval for a cancer gene therapy was granted in China in 2003, no European approval has been granted until now.

LPLD is a disease which results in an inability to digest fat properly, leading to repeated bouts of inflammation of the pancreas, early onset diabetes and cardiovascular complications. It affects up to one to two people per million worldwide. Protein replacement therapy provides a temporary fix for many genetic diseases, however it is not available for the treatment of LPLD.

Professor John Kastelein from the Department of Vascular Medicine at the University of Amsterdam, the Netherlands commented, '[Glybera] will have a dramatic impact on the lives of these patients. Currently their only recourse is to severely restrict the amount of fat they consume. By helping to normalise the metabolism of fat, Glybera prevents inflammation of the pancreas thereby averting the associated pain and suffering and, if administered early enough, the associated co-morbidities'.

UniQure is currently planning to apply for regulatory approval for Glybera in other markets including the USA and Canada. Mr Aldag said, 'The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need'.

Clinical trials of gene therapy in Parkinson's disease (reported in BioNews 652) and cystic fibrosis (reported in BioNews 649) are already underway in the UK.

SOURCES & REFERENCES
Europe approves high-price gene therapy
Reuters |  2 November 2012
Gene therapy: Glybera approved by European Commission
BBC News |  2 November 2012
uniQure’s Glybera First Gene Therapy Approved by European Commission
UniQure (press release) |  2 November 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
24 April 2017 - by Kulraj Singh Bhangra 
A million-dollar gene therapy treatment for a rare blood disease will be withdrawn from the European market due to lack of demand...
6 June 2016 - by Rachel Reeves 
The European Commission has granted marketing authorisation for a gene therapy to treat children with an extremely rare, life-threatening genetic disorder...
11 April 2016 - by Rebecca Carr 
A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency...
14 December 2015 - by Dr James Heather 
Two patients enrolled in a clinical trial of a gene therapy to treat severe congenital immunodeficiency have shown signs of substantial improvement in their condition...
1 December 2014 - by Arit Udoh 
Glybera, the first gene therapy to go on sale in Europe, is set to cost €1.1m (£870,000) per patient, making it the world's most expensive drug...
2 December 2013 - by Dr Rachel Brown 
A biotech start-up that will develop genome-editing therapies has received US $43 million investment from three venture capital firms...
11 November 2013 - by Dr Naqash Raja 
The Children's Hospital of Philadelphia has invested US $50 million in a biotech start-up in an effort to commercialise gene therapy...
7 October 2013 - by Dr Shanya Sivakumaran 
The Alkaptonuria Society, a UK charity and patient organisation for the rare disease of the same name, has won a £5million grant from the European Commission to help finance clinical trials of a treatment for the condition...
9 September 2013 - by James Brooks 
A parliamentary report has recommended a ring-fenced fund to ensure access to 'low volume, high cost' treatments for rare diseases...
15 July 2013 - by Dr Nicola Davis 
A clinical trial of a gene therapy to treat children with two types of severe genetic disease has shown early signs of success...
17 December 2012 - by Joseph Jebelli 
A seven-year-old girl with a highly aggressive form of leukaemia may have been 'cured' by an experimental therapy that harnesses the body's immune system to seek out and destroy the disease....
18 February 2012 - by Rachel Lloyd 
The principal purpose of Professor Emily Jackson's book, Law and the Regulation of Medicines, is to outline medicine's journey through UK regulation. Jackson seeks to show that those responsible for the content of the regulatory regime, and the way in which it is administered, play a crucial role in shaping the development, supply and marketing of medicines....
30 July 2012 - by Dr Rosie Gilchrist 
The European Medicines Agency has recommended European Union market approval for a gene therapy, Glybera, to treat patients with severe cases of a rare genetic condition called lipoprotein lipase deficiency...
21 May 2012 - by Victoria Kay 
The world's first stem cell drug has been approved by Canadian authorities. US biotech company, Osiris Therapeutics, has been given the go-ahead to market its drug, Prochymal, for the treatment of graft-versus-host-disease (GvHD) in children who fail to respond to steroids....
8 May 2012 - by Helen Brooks 
HIV patients treated over a decade ago with genetically modified immune cells have suffered no serious side effects from the treatment. Although the cells may not have been successful in targeting and killing HIV-infected cells, the results are promising as they bolster the safety credentials of gene therapy for clinical use...
16 April 2012 - by Dr Kimberley Bryon-Dodd 
A woman with Parkinson's disease is reportedly able to write again for the first time in 15 years after receiving pioneering gene therapy at Addenbrooke's Hospital, Cambridge. Mrs Shelia Roy took part in an early stage clinical trial of ProSavin - a treatment developed by biopharmaceutical company, Oxford BioMedica....
19 March 2012 - by Heidi Colleran 
The largest trial for a gene therapy for cystic fibrosis (CF) will begin in the UK this month. Coordinated by the UK Cystic Fibrosis Gene Therapy Consortium (GTC), 130 patients will be recruited and given working copies of the defective gene that leads to their condition...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.